MVASI
Biological
Amgen Inc.
Total Payments
$678,732
Transactions
2,945
Doctors
1,832
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $461,343 | 7 | 1 |
| 2022 | $4,069 | 4 | 4 |
| 2021 | $25,873 | 57 | 39 |
| 2020 | $59,320 | 214 | 136 |
| 2019 | $128,127 | 2,663 | 1,759 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $497,813 | 15 | 73.3% |
| Consulting Fee | $83,413 | 33 | 12.3% |
| Food and Beverage | $48,226 | 2,867 | 7.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,824 | 20 | 6.2% |
| Space rental or facility fees (teaching hospital only) | $5,500 | 4 | 0.8% |
| Travel and Lodging | $1,956 | 6 | 0.3% |
Payments by Type
Research
$497,813
15 transactions
General
$180,919
2,930 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $459,693 | 0 |
| Published online ABP 215 Review (Oncology and Therapy) | Amgen Inc. | $16,919 | 1 |
| ABP 215 Safety Effectiveness Study in mCRC | Amgen Inc. | $9,654 | 1 |
| Publication ABP 215 Review (Immunotherapy) | Amgen Inc. | $7,198 | 1 |
| A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer | Amgen Inc. | $2,511 | 0 |
| Real-World Utilization of MVASI in A Retrospective Observational Study Using OSCER Database | Amgen Inc. | $1,838 | 0 |
Top Doctors Receiving Payments for MVASI — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Powell, TN | $62.25 | 3 |
| , M.D | Hematology & Oncology | Knoxville, TN | $62.20 | 5 |
| Balagopal Keralavarma | — | Munster, IN | $62.18 | 3 |
| , MD | Hematology & Oncology | Chicago, IL | $61.99 | 2 |
| , MD | Hematology & Oncology | Yorktown Heights, NY | $61.92 | 4 |
| , M.D | Hematology & Oncology | Charleston, SC | $61.87 | 3 |
| , MD | Medical Oncology | Indianapolis, IN | $61.62 | 4 |
| , M D | Medical Oncology | Miramar, FL | $61.02 | 6 |
| , M.D | Hematology & Oncology | Bayamon, PR | $61.00 | 3 |
| , M.D | Hematology & Oncology | Hartford, CT | $60.82 | 4 |
| , MD | Hematology & Oncology | Hartford, CT | $60.82 | 4 |
| Drew Murray | Internal Medicine | Louisville, KY | $60.14 | 5 |
| , M.D | Medical Oncology | Athens, GA | $59.99 | 4 |
| , MD | Hematology | Cheyenne, WY | $59.88 | 3 |
| , M.D | Hematology & Oncology | Findlay, OH | $59.67 | 4 |
| , MD, MPH | Internal Medicine | Galveston, TX | $59.41 | 3 |
| , MD | Hematology & Oncology | Vallejo, CA | $59.19 | 3 |
| , M.D | Internal Medicine | Lexington, KY | $58.01 | 3 |
| , M.D | Medical Oncology | Sebring, FL | $58.01 | 3 |
| , M.D | Internal Medicine | Encinitas, CA | $57.87 | 2 |
| , M.D | Hematology & Oncology | Visalia, CA | $57.77 | 3 |
| , MD | Hematology & Oncology | San Antonio, TX | $57.75 | 2 |
| , MD | Surgical Oncology | San Diego, CA | $57.61 | 2 |
| , M.D | Internal Medicine | Newport Beach, CA | $57.42 | 2 |
| , M.D | Hematology & Oncology | Downey, CA | $57.40 | 2 |
Ad
Manufacturing Companies
- Amgen Inc. $678,732
Product Information
- Type Biological
- Total Payments $678,732
- Total Doctors 1,832
- Transactions 2,945
About MVASI
MVASI is a biological associated with $678,732 in payments to 1,832 healthcare providers, recorded across 2,945 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2019 to 2023. In 2023, $461,343 was paid across 7 transactions to 1 doctors.
The most common payment nature for MVASI is "Unspecified" ($497,813, 73.3% of total).
MVASI is associated with 6 research studies, including "AMG 510 Ph1b Master Protocol 20190135" ($459,693).